A randomized trial on effects of hormone therapy on ambulatory blood pressure and lipoprotein levels in women with coronary artery disease

Journal of Hypertension

Volumn 17, Issue 10, 1999, Pages 1379-1386

  Pripp, Ulla ^a   Hall, Gerd ^b   Csemiczky, György ^b   Eksborg, Staffan ^a   Landgren, Britt Marie ^b   Schenck Gustafsson, Karin ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Ambulatory blood pressure; Coronary artery disease; Hormones; Lipoprotein levels; Women

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; CONJUGATED ESTROGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ESTRADIOL; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MEDROXYPROGESTERONE ACETATE; NITRATE; THYROID HORMONE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFECT; FEMALE; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; NIGHT; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TRANSDERMAL DRUG ADMINISTRATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0032759063     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199917100-00004     Document Type: Article

References (48)

1. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study. N Engl J Med 1991; 325:756-762.
2. Nabulsi AA, Folsom AR, White A, Patsch W, Heiss G, Wu KK, et al. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med 1993; 328:1069-1075.
3. Rich-Edwards JW, Manson JE, Hennekens CH, Buring JE. The primary prevention of coronary heart disease in women. N Engl J Med 1995; 232: 1758-1766.
4. Falkeborn M, Persson J, Adami H, Bergström R, Eaker E, Lithell H, et al. The risk of acute myocardial infarction after estrogen-progesteron replacement. Br J Obstet Gynaecol 1992; 99:821-828.
5. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280:605-613.
6. Collins P, Burman J, Chung H-I, Fox K. Hemoglobin inhibits endothelium-dependent relaxation to acetylcholine in human coronary arteries in vivo. Circulation 1993; 87:80-85.
7. Gilligan DM, Quyyumi AA, Cannon RO III. Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation 1994; 89:2545-2551.
8. Reis SE, Gloth ST, Blumenthal RS, Resar JR, Zacur HA. Gerstenblith G, et al. Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal woman. Circulation 1994; 89:52-60.
9. Collins P, Rosano GMC, Sarrel PM, Ulrich L, Adamopoulus S, Beale CM, et al. 17β-estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation 1995; 92:24-30.
10. Al-Khalili F, Eriksson M, Landgren B-M, Schenck-Gustafsson K. Conjugated estrogen induces acute improvement of the peripheral flow-mediated vasodilation in postmenopausal women. Am J Cardiol 1998; 82:215-233.
11. Collins P, Rosano GMC, Jiang C, Lindsay D, Sarrel PM, Poole-Wilson PA. Cardiovascular protection by oestrogen-a calcium antagonist effect? Lancet 1993; 341:1264-1265.
12. Rosano GMC, Sarrel PM, Poole-Wilson PA, Collins P. Beneficial effect of oestrogen on exercise-induced myocardial ischemia in women with coronary artery disease. Lancet 1993; 342:133-136.
13. Rosano GMC, Petors NS, Lefroy D, Lindsay DC, Sarrel PM, Collins P, et al. 17-beta-estradiol therapy lessens angina in postmenopausal women with syndrome X. J Am Coll Cardiol 1996; 28:1500-1505.
14. Al-Khalili F, Landgren B-M, Eksborg S, Franco-Cereceda A, Schenck-Gustafsson K. Does sublingual 17β-oestradiol have any effects on exercise capacity and myocardial ischaemia in post-menopausal women with stable coronary artery disease? Eur Heart J 1998; 19:1019-1026.
15. Barrett-Connor E, Miller V. Estrogens, lipids and heart disease. Clin Geriatr Med 1993; 9:57-67.
16. Sacks FM, Walsh BW. Sex hormones and lipoprotein metabolism. Curr Opin Lipidol 1994; 5:236-240.
17. Bonithon-Kopp C, Scarabin P-Y, Darne B, Malmejac A, Guize L. Menopause-related changes in lipoproteins and some other cardiovascular risk factors. Int J Epidemiol 1990; 19:42-48.
18. Bush TL, Barrett-Connor E, Cowan LD, Criqui MH, Wallace RB, Suchindran CM, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987; 75:1102-1108.
19. Lobo RA. Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women. J Clin Endocrinol Metab 1991; 73:925-930.
20. Stevenson JC, Crook D, Godsland IF. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis 1993; 98:83-90.
21. Sarrel P. Ovarian hormones and the circulation. Maturitas 1999; 590:287-298.
22. Barrett-Connor E, Wingard DL, Criqui MH. Postmenopausal estrogen use and heart disease risk factors in the 1980s. JAMA 1989; 261:2095-2100.
23. Hassager C, Riis BJ, Strøm V, Guyene TT, Christiansen C. The long-term effect of oral and percutaneous estradiol on plasma renin substrate and blood pressure. Circulation 1987; 76:753-758.
24. Lip GYH, Beevers M, Churchill D, Beevers DG. Hormone replacement therapy and blood pressure in hypertensive women. J Hum Hypertens 1994;8:491-494.
25. Akkad AA, Halligan AWF, Abrams K, Al-Azzawi F. Differing responses in blood pressure over 24 hours in normotensive women receiving oral or transdermal estrogen replacement therapy. Obstet Gynecol 1997; 89:97-103.
26. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestir Interventiones (PEPI) Trial. JAMA 1995; 273:199-208.
27. Mashchak CA, Lobo RA. Estrogen replacement therapy and hypertension. J Reprod Med 1985; 30:805-810.
28. Darling GM, Johns JA, McCloud PI, Davis SR. Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women. N Engl J Med 1997; 337:595-601.
29. Campeau L. Grading of angina pectorie. Circulation 1976; 43:522.
30. World Health Organization. Obesity, Preventing and managing the global epidemic. Report of a World Health Organisation Consultation on Obesity. Geneva: WHO; 1997. WHO/NUT/NCD/98.1 3-5.
31. O'Brien E, Mee F, Atkins N, O'Malley K. Accuracy of the Space Labs 90207 determined by the British Hypertension Society Protocol. J Hypertens 1991; 9:573-574.
32. Aedo AR, Le Donne M, Landgren BM, Diczfalusy E. Effect of orally administered oestrogens on gonadotrophin levels in post-menopausal women. Maturitas 1989; 11:147-157.
33. Cooper GR, De Keersgleter W, Ezcurra EJ, Rosseneu M, Shepherd J, d'Arcangues C. Method Manual For Lipid, Lipoprotein and Apolipoprotein Determinations. 1989.
34. Treatment of Hyperlipidemia. Medical Products Agency. 1996:2
35. Verdecchia P, Porcellati C, Schillaci G, Borgioni C, Ciucci A, Battistelli M, et al. Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension 1994; 24:793-801.
36. Mancia G, Zanchetti A, Agabiti-Rosei E, Benemio G, De Cesaris R, Fogari R, et al. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on ambulatory monitoring of blood pressure and lisinopril evaluation. Circulation 1997; 95:1464-1470.
37. Mashchak CA, Lobo RA, Dozono-Takano R, Eggena P, Nakamura RM, Brenner PF, et al. Comparisons of pharmacodynamic properties of various etrogen formulations. Am J Obstet Gynecol 1982; 144:511-518.
38. Myers MG, Reeves RA. White coat effect in treated hypertensive patients: sex differences. J Hum Hypertens 1995; 9:729-733.
39. Verdecchia P, Schillaci G, Gatteschi C, Zampi I, Battistelli M, Bartoccini C, et al. Blunted nocturnal fall in blood pressure in hypertensive women with future cardiovascular morbid events. Circulation 1993; 88:986-992.
40. Shionori H, Eggena P, Barrett JD. An increase in high-molecular-weight renin-substrate associated with estrogenic hypertension. Biochem Med 1983; 29:14-22.
41. Wren BG. Hypertension and thrombosis with postmenopausal estrogen therapy. In: Studd JJW, Whitehead M (editors): The Menopause. London: Blackwell Scientific Publications; 1988. pp. 181-189.
42. Hall G, Pripp U, Schenck-Gustafsson K, Landgren B-M. Long-term effects of hormone replacement therapy on symptoms of angina pectoris, quality of life and compliance in women with coronary artery disease. Maturitas 1998; 28:235-242.
43. Horsten M, Kirkeeide R, Wamala S, Svane B, Orth-Gomér K, Rydén L, et al. Social factors and extent and severity of coronary artery disease in women. Eur Heart J 1998; 19:1648-1656.
44. Lobo RA, Whitehead MI. Too much of a good thing? Use of progestogens in the menopause: an international consensus statement. Fertil Steril 1989;51:229-231.
45. Lindsay R, Herrington BS: Estrogens and osteoporosis. Semin Reprod Endocrinol 1983; 1:55-67.
46. Stevenson JC, Crook D, Godsland IF, Lees B, Whitehead MI. Oral versus transdermal hormone replacement therapy. Int J Fertil 1993; 38:30-35.
47. Jacobs DR, Mebane IL, Bangdiwala SI, Criqui MH, Tyroler HA. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinics Prevalence Study. Am J Epidemiol 1990; 131:32-47.
48. Marchesoni D, Dal Pozzo M, Dal Magro L, Ferroni E, Maggino T, Maggino T, et al. Transdermal estroprogestins versus transdermal estrogen plus oral dihydrogester dihydrogesterone replacement in menopause. J Endocrinol Invest 1996; 19:268-272.